Clinical Trials Logo
  1. Home
  2. Lung Transplantation
  3. NCT05837663
  4. Details
NCT05837663 Clinical Trial

Trifecta-Lung cfDNA-MMDx Study

Lung Transplantation Clinical Trial

Official title:
Trifecta-Lung cfDNA-MMDx Study: Comparing the Dd-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05837663
Other study ID # Pro00048176
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date December 2025

Study information
Verified date February 2024
Source University of Alberta
Contact Konrad S Famulski, PhD DSc
Phone 1 780 782 9463
Email konrad@ualberta.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.

Description:

The current standard for assessment of rejection in lung transplants is a transbronchial biopsy (TBB) interpreted by histology according to International Society of Heart and Lung Transplantation (ISHLT) guidelines. This has considerable error rates, many due to the high disagreement among pathologists. There is a need for new methods of assessing TBBs. In addition, the emergence of blood donor-derived cell-free DNA (dd-cfDNA) measurement offers a new opportunity for screening for rejection. To address the unmet need for precision and accuracy, the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system - the Molecular Microscope® Diagnostic System (MMDx), which uses microarrays to define the genome-wide gene expression and interpret lung transplant rejection and injury ((chronic lung allograft dysfunction (CLAD) related changes)). Now a new screening test is being introduced: the monitoring of dd-cfDNA released in the blood by the heart during rejection. The Natera Inc dd-cfDNA Prospera® test is based on the massively multiplex polymerase chain reaction that targets 13,392 single nucleotide polymorphisms and targeted sequences are quantified by Next Generation Sequencing. The Prospera® test has been done on kidney transplant recipients and detected "active rejection" and differentiated it from borderline rejection and no rejection. However, Prospera® test was not examined (the dd-cfDNA results) in lung transplant recipients. dd-cf-DNA test for lung transplants must now be calibrated against MMDx that is based on global gene expression, the new standard for biopsy interpretation. The present study will calibrate centrally measured (Natera Inc) dd-cfDNA levels obtained at the time of an indication or protocol biopsy against the MMDx measurements of T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR-like) and tissue injury. The present study will compare dd-cfDNA and MMDx in 600 prospectively collected biopsies for clinical indications and protocol, and accompanying 1800 blood samples, to calibrate the dd-cfDNA (Natera Inc.) levels against the MMDx biopsy diagnoses of TCMR, ABMR-like (and its stages), and injury, as well as central assessment of Human Leukocyte Antibody (HLA) antibody (One Lambda), interpreted centrally as donor specific antibody (DSA) based on the tissue typing results. This study is an extension of the INTERLUNG ClinicalTrials.gov identifier: NCT02812290

Recruitment information / eligibility
Status Recruiting
Enrollment 600
Est. completion date December 2025
Est. primary completion date November 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Adult, Older adult Exclusion Criteria: Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Australia The Alfred Hospital, Monash University Melbourne
Austria Department of Thoracic Surgery, Medical University of Vienna Vienna
Canada Alberta Transplant Applied Genomics Centre, University of Alberta Edmonton Alberta
Canada Department of Medicine, University of Alberta Edmonton Alberta
Canada University Health Network, Toronto General Hospital Toronto Ontario
Czechia Charles University/Hospital Motol Prague
Czechia Motol University Hospital, V Uvalu 84 Prague

Sponsors (3)
Lead Sponsor Collaborator
University of Alberta Natera, Inc., One Lambda

Countries where clinical trial is conducted

Australia,  Austria,  Canada,  Czechia, 

Outcome
Type Measure Description Time frame Safety issue
Primary Calibration of Prospera® test for T cell mediated rejection Set dd-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. Calibration of dd-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. 18 months
Primary Calibration of Prospera® test for antibody-mediated rejection Set dd-cfDNA test cut-off values against the probability of antibody-mediated rejection in the biopsy as reported by MMDx. 18 months
Primary Calibration of Prospera® test for lung injury Set dd-cfDNA test cut-off values against the probability of acute and chronic lung injury in the biopsy as reported by MMDx. 18 months
Primary Report calibrated Prospera® test results for rejection Report new dd-cfDNA test cut-off values for rejection 6 months
Primary Report calibrated Prospera® test results for lung injury Report new DD-cfDNA test cut-off values for lung injury 6 months
Secondary Assessment of donor-specific antibody status Record and compare the DSA status (positive or negative) based on centralized and local HLA antibody to histology diagnoses.. 6 months
Secondary .Estimate the false positive rate of dd-cfDNA for MMDx and histology in indication and protocol biopsies Calculate the sensitivity and specificity of dd-cfDNA for MMDx and histology diagnoses. 6 months
Secondary Determine whether calibrated dd-cfDNA blood test will replace biopsies Determine if dd-cfDNA test will avoid need for indication biopsy when transplant function deteriorates - yes or no. This will be based on the consensus between participating clinicians. 6 months
Secondary Determine whether calibrated dd-cfDNA blood test predicts the effect of treatment Determine the values for dd-cfDNA for grades of response to treatment: no change, partial response, complete resolution. 6 months
See also
  Status Clinical Trial Phase
Completed NCT02581111 - Naloxone for Optimizing Hypoxemia Of Lung Donors Phase 2/Phase 3
Recruiting NCT02177916 - Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation N/A
Not yet recruiting NCT01394835 - Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients Phase 2
Completed NCT01204970 - Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients N/A
Not yet recruiting NCT01162148 - Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation N/A
Active, not recruiting NCT00980967 - Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study N/A
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Recruiting NCT00163696 - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease N/A
Completed NCT00177684 - Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Phase 3
Completed NCT00163891 - Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients N/A
Completed NCT03668483 - Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx N/A
Not yet recruiting NCT02855372 - Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT) N/A
Completed NCT01212406 - Vitamin D in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT01211509 - Montelukast in Bronchiolitis Obliterans Syndrome Phase 4
Not yet recruiting NCT00808600 - Empowerment of Lung and Heart-lung Transplant Patients N/A
Completed NCT00553397 - Live Lung Donor Retrospective Study N/A
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Terminated NCT00235651 - Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients Phase 3
Active, not recruiting NCT02936505 - Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD. N/A